Procter & Gamble said its $4.2 billion acquisition of German firm Merck's consumer health division was about allowing it to respond to the changing demands of an aging world.
Scott Dulitz, SVP, Corporate Strategy, Business Development for TrialCard, outlines how embracing the modern hub allows brands to reach their full potential.
Jim Boushie, director of respiratory marketing at Boehringer Ingelheim (BI) and David Laros, VP of analytics and commercial effectiveness at Aptus Health, came together to lead a joint ePharma session in March titled "Synchronized HCP and consumer campaigns: At the point of care and beyond."
The company is also looking to better combine its web and social media presence.
In an effort to assure advertisers and agencies on brand safety, Google has announced two new requirements for video creators that intend to join the YouTube Partner Program.
Facebook's decision to reprioritise its news feed to favour "social interactions" over other forms of content may please its users but will be challenging for brands.
Cancer Research UK's 'Right Now' brand campaign will return in 2018 with a new focus highlighting the impact that research has on people suffering with cancer.
Brands should refrain from tweets that are over 100 characters, according to Twitter's director of brand strategy.
FDA approves Novo's diabetes drug; Walgreens undergoes rebranding in the wake of CVS-Aetna merger; pharma increasingly transparent about clinical trial data
In April, a month or so after brands were accused of funding terrorist videos on YouTube, Procter & Gamble cut down the number of sites its ads ran on by 69%.
Porter Novelli has been appointed to lead a new global CSR brief for pharma and consumer goods giant Johnson & Johnson, as the company faces a major reputation challenge in the US.
The new brand campaign, Attacking Cancer from Every Angle, showcases all the services the organization provides.
The rise of voice technology platforms and the connected home has turned the discussion of a brand's voice from metaphorical to physical.
Aaron Sklar, formerly of Welltok, replaces Christine Armstrong, who moved on to a Silicon Valley health startup.
She is director of OTC brand marketing at Dr. Reddy's Laboratories.
Celgene's Revlimid tops the list, according to data compiled by EvaluatePharma.
Twitter has launched a customizable Direct Message Card that brands can use to promote and share the bots or other customer experiences they've created, while Snapchat and Instagram have launched stories updates.
The drugmaker saw a gap in patient-physician conversation about retinal disease.
As we build health solutions, making decisions in office parks and around conference tables, it's easy to lose the individual person through the scale of our work.
The presumption is Dr. A saw ad B, clicked on it, went to the site and within C time, prescribed product D.
"Find exactly what your audience wants, find exactly where they spend their time, and deliver."
The connection to Pristiq is not overt in the app's user interface, though Moodivator is featured on Pristiq's website.
Pharma can reach physicians within the EHR, but they must send the right message at the right time, she said at an MM&M event.
Companies such as Eli Lilly and Medtronic have launched branded apps for their products, but experts say they don't make sense for all medicines.
In the United States, people over 50 are often stereotyped as complacent, set in their ways and extremely loyal to their preferred brands, but a new study released Tuesday by Ketchum found that the opposite is true.
CDM New York populated this engaging and outstanding website for Salix with unique visuals and messaging elements designed to drive awareness.
In this sponsored podcast, MM&M's Larry Dobrow speaks with Robert Leedom, senior analytics consultant at TrialCard, and Paul LeVine, VP of analytic services for TrialCard, about how to reach patients by leveraging brand data.
Patients who ask for a prescription after seeing an ad are more likely to get one; Mylan's executive pay is now under scrutiny
In 2011 the drugmaker spent $9.4 million on branded ads for the EpiPen. By 2015, branded ad spending hit $43 million.
Will this payer pressure pose an existential threat to co-pay cards even though patients love them?